EDP167 not checked
Eddingpharm (Zhuhai) Co., Ltd.
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “EDP167 100 mg or volume-matched placebo sc once every 12 weeks in the core study, and EDP167 100 mg once every 3 months in the extension study.”In the company’s words, NCT07799129 on ClinicalTrials.gov
- Main trialPhase 2
- “EDP167 is a double-stranded small interfering RNA (siRNA) drug targeting angiopoietin-like 3 protein (ANGPTL3), which may bring benefits for patients with dyslipidemia conditions. This is a dose exploration study in Homozygous Familial Hypercholesterolaemia (HoFH) patients to evaluate the efficacy and safety and pharmacokinetics (PK)/pharmacodynamics (PD) profiles of multiple EDP167 injections.”In the company’s words, NCT07489209 on ClinicalTrials.gov
Other drugs for Homozygous Familial Hypercholesterolemia (HoFH)
- ZodasiranArrowhead · Phase 3
- InclisiranNovartis Pharmaceuticals · Phase 3
- VSA003Visirna Therapeutics HK Limited · Phase 3
- SHR-1918Hengrui · Phase 2
- CTX310CRISPR Therapeutics AG · Phase 1
Coming up1
- Nov 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 4 Oct 2026 | A Dose-exploration Study of EDP167 in HoFH | |
| Phase 2Not yet recruiting | Nov 2027 | Phase 2 Dose-Finding Study Evaluating the Efficacy and Safety of EDP167 in Adults With Mixed Dyslipidemia | |
| Phase 1Completed | 12 Dec 2025 | EDP167 in Healthy Volunteers and Subjects With Mild Dyslipidemia |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026